Atossa Therapeutics Releases Preliminary Analysis From Phase 2 Trial Of (Z)-endoxifen As Part Of I-SPY 2 Endocrine Optimization Pilot Will Be Subject Of Poster Presentation At Inaugural RISE UP Breast Cancer Conference
Atossa Therapeutics Releases Preliminary Analysis From Phase 2 Trial Of (Z)-endoxifen As Part Of I-SPY 2 Endocrine Optimization Pilot Will Be Subject Of Poster Presentation At Inaugural RISE UP Breast Cancer Conference
atossa therapeutics發佈了(Z)-endoxifen的2期試驗初步分析結果，作爲I-SPY 2內分泌優化試點項目的一部分，將在首屆RISE UP乳腺癌大會上做海報展示的主題
(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial
(Z)-每日一次 10 mg 的內多昔芬達到了主要終點，在 I-SPY-2 2 期試驗中，19/20 (95%) 接受了超過 75% 的計劃治療量
Low dose (Z)-endoxifen was well tolerated and demonstrated promising rapid activity in reducing 3-wk Ki-67 and FTV Biomarkers
低劑量 (Z)-內氧芬耐受性良好，在減少3周Ki-67和FTV生物標誌物方面表現出良好的快速活性
資訊熱榜
更新時間